Diabetic Macular Edema Visual Outcomes Predictable With OCT Biomarkers
Baseline OCT biomarkers may predict visual outcomes in patients with center-involving diabetic macular edema.
Certain biomarkers, such as hyperreflective foci (HRF), disrupted ellipsoid zone (EZ)/external limiting membrane (ELM), disorganization of retinal inner layers (DRIL), and hyperreflective choroidal foci (HCF), have the potential to serve as predictors of poorer vision in patients with center-involving diabetic macular edema (CI-DME).
Researchers conducted a systematic review and meta-analysis to evaluate the prognostic significance of baseline structural optical coherence tomography (OCT) biomarkers in patients with CI-DME undergoing anti-vascular endothelial growth factor (VEGF), steroid, or laser therapy.
- Assessing their associations with visual acuity (VA) levels
- Changes in VA at 6, 12, and 24 months after treatment initiation
According to study results published in the American Journal of Ophthalmology.
Author's summary: OCT biomarkers predict visual outcomes in diabetic macular edema patients.